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1207-152 Use of Atropine in Patients With Poor Chronotropic 
Response During Treadmill Stress Testing 
Viiava K. Munaaala, Vamshidhar Guduguntla, Babak Kasravi, Glen Cummings, Julius M. 
Gardin, St. John Hospital & Medical Center, Detroit, Michigan, University of California- 
Irvine, Orange, California. 
Background Treadmill stress testing (TMST) is a valuable diagnostic test for ischemic 
heart disease. However sub-maximal exercise (achieving < 85% of maximum predicted 
heart rate) secondary to fatigue, medications, etc. is a major limitation to its utility. We 
evaluated the usefulness of atropine in decreasing the number of inconclusive tests in 
patients with a poor chronotropic response to TMST. 
Methods The study was comprised of 126 patients undergoing TMST. Atropine was 
administered to subjects experiencing fatigue at sub-maximal exercise in doses of 0.5 
mg/minute until test conclusion (a positive test or target heart rate achieved) or until a 
maximum dose of 2 mg. 
Results Thirty- three of the 126 subjects (26%) required atropine (mean dose 1 mg) dur- 
ing the study; 23 of the 33 subjects (70%) proceeded to achieve their target heart rate 
(n=17) or a positive test (n=6). Mean increase in heart rate after atropine administration 
was 25 beats/min (range 3-53 beats/min); Atropine was required in 39% of patients 
receiving, versus 21% not receiving, beta-blockers (p=0.02). Among subjects receiving 
atropine, a conclusive test was achieved significantly more often in those not receiving 
beta-blockers (94% vs. 46%, p=0.01). No adverse events were associated with the use 
of atropine. 
Conclusion Use of atropine as an adjunct to standard TMST can help decrease the 
number of inconclusive tests - even in patients taking beta-blockers. Larger studies are 
warranted to further define the role of atropine in diagnostic TMST. 
Effect of Beta-Blocker use on TMST outcome in Atropine recipients 
Beta-Blockers Conclusive tests Inconclusive tests 
Yes 7(46%) 8(54%) 
No 14(94%) 1(6%) 
1207-153 Radiofrequency Ablation of Typical Atrial Flutter: 
Immediate Hemodynamic and Cardiorespiratory Benefit 
for the Patient? 
Rainer Schimof, Heycler Omran, Christian Wolpert, Alexander Yang, Susanne Herwig, 
Kyung-Mi Jeong, Thorsten Lewalter, Berndt L~deritz, Department of Medicine- 
Cardiology, University of Bonn, Bonn, Germany. 
Patients with persistent atrial flutter (AFL) can be effectively treated by radiofrequency 
ablation in the cavo-tricuspid isthmus. Despite a more regular excitation and contraction 
than atdal fibrillation the prognostic effect of the ablation therapy and time course of sub- 
maximal hemodynamic and cardiorespiratory function has not been investigated so far. 
Methods: The patients were exercised on a treadmill following the LITE ("Low Intensity 
Treadmill Exercise") protocol before, one day and one month after the procedure. Spiro- 
ergometry and transthoracic echocardiography were performed. With "breath by breath" 
technique oxygen uptake kinetics were analyzed (O2-k), pulmonary artery pressure 
(PAP), left atrial peak A-wave velocity (LAV) and ejection fraction (EF) were determined 
by echocardiography. Results: One month after ablation 15 from 17 patients remained in 
sinusrhythm (mean age 58 +/- 11.2 years). The time to reach steady state, oxygen deficit, 
mean response time of oxygen uptake (MRT) were different at one month in comparison 
to the first day after the procedure. LAV increased significantly after one month (s.Table). 
Despite a more regular excitation and contraction during AFL atrial function remains 
depressed early after regularisstion and recovers delayed. Clinical implication: Radiofre- 
quency ablation therapy of persistent atrial flutter shows a relevant but delayed and not 
immediate hemodynamic and cardiorespiretory benefit at daily submaximal exercise lev- 
els. 
Cardiorespiretory and hemodynamic parameters before 
and after ablation of persistent atrial flutter 
(* p< 0.05) STS (sec) 02-clef (ml) MRT (sec) EF (%) LAY (m/sec) PAP (mmHg) 
before 127+/-21 470+/-110 59+/-18 49+/-10 29+/-10 
1day 110+/-13 390+/-21 62+/-16 49+/-14 0.26+/-0.06 26+/-6 
1month 79+/-14" 280+/-35* 41 +/-16" 56+/-17 0.46+/-0.3* 17+/-4 
1207-154 Interpretation Error of Peak and Anaerobic Threshold 
Oxygen Consumption in Heart Failure Patients During 
Maximal Exercise: Implications for Measuring 
Diminutive Treatment Effects of Intervention 
Donald L. HODDer. Michael Higginbotham, Fred L Ecklund, Julie M. West, Jay 
Millerhagen, Donna Tranchida, Jay Warren, Guidant Corporation, SL Paul, Minnesota, 
Duke University, Durham, North Carolina. 
Background: Various methods of cardiopulmonary exercise tests to determine peak and 
Anaerobic Threshold (AT) VO2 have been developed. While repeated testing is widely 
employed, error in the interpretation of the data has not been well defined. Two inde~ben- 
dent reviewers, A and B, used the following method to determine peak and AT VO2 from 
50 maximal CPX tests performed by 42 heart failure patients (31 males, mean age 65.4; 
11 females, mean age 65,5), with NYHA class II (10), UI (27) and IV (5). 
Methods: Parameters of minute ventilation (VE), oxygen consumption (V02), respiratory 
exchange ratio (RER), carbon dioxide production (VCO2), and the relationships of VE/ 
V02, VENC02 were plotted against time. Peak V02 was determined by averaging the 
V02 values over the last 15 seconds of exercise; the corresponding RER value was used 
to confirm maximal effort. VO2 at AT was determined by standard criteria from the rela- 
tionships of VE/VO2 and VENCO2. 
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Results: There was no significant difference in mean peak V02, between reviewers, (A: 
13.58 _+ 3.75 vs. B: 13.47 + 3.76 p=. 88), and AT (A: 11.10 + 2.99 vs. B: 10.15 +_ 2.45 p=. 
08). The correlation coefficients for peak VO2 and AT respectively were +0.99 and +0.84. 
Conclusion: A standardized methodology to interpret peak VO2 reduces interpretation 
error and consistent results can be obtained. However, the interpretation of VO2 at AT 
has greater variability and is expected to be less precise for determining serial changes. 
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876 Gene Expression in Heart Failure 
Tuesday, March 19, 2002, 4:00 p.m.-5:00 p.m. 
Georgia World Congress Center, Room 260W 
4:00 p.m. 
876-1 Altered Gone Expression Profile in Skeletal Muscle 
After Development of Chronic Heart Failure 
Nicolle Krankel. Volker Adams, Stephan Gielen, Rainer Hambrecht, Gerhard Schuler, 
University of Leipzig, Heart Center Leipzig, Leipzig, Germany. 
Background: Different intrinsic alterations of skeletal muscle (SM) metabolism and gene 
expression have been described in chronic heart failure (CHF). These studies, however 
have only analyzed the differential expression of selected genes, therefore their gain of 
new information is limited. The aim of this study was to compare the gene expression 
profile in SM of rats with CHF and healthy controls. In a second step the findings of the 
animal model were tested in skeletal muscle biopsies of CHF patients. 
Methods: The animals were subjected to either LAD ligation or sham operation. Twelve 
weeks after LAD ligation myocardial infarction was confirmed by echocardiography. 
mRNA was isolated from m. quadriceps of 5 CHF rats and 5 sham operated controls. Dif- 
ferential gone expression was studied by suppression subtractive hybridization. Expres- 
sion of selected genes was further analyzed in SM biopsies of CHF patients and healthy 
controls by quantitative RT-PCR. 
Results: Out of 800 picked clones the differential expression of 120 different sequences 
(15%) could be verified by reverse Northern analysis. Genebank survey revealed the 
identity of 99 genes, whereas 21 sequences did not show homology to any known 
sequence. Out of the 60 non-mitochondrial fragments 24 distinct genes were identified. 
Differential expression of Mss 4, protein phosphatase 2A (PP2A), calsarcin-2 and con- 
taurin-a2 was confirmed by quantitative RT-PCR in SM biopsies of CHF patients and 
healthy controls. Especially PP2a may reduce SERCA activity via dephosphorylation of 
phospholamban and increase the apoptotic rate by dephosphorylation of Bcl-2 and Bad. 
Conclusion: The results of this study indicate that a variety of genes involved in energy 
metabolism, contraction, cell signaling and exocytosis are differentially expressed in SM 
of CHF patients, possibly contributing to the reduction of contractile force and increased 
rate of apoptosis. 
4:1 5 p.m. 
876-2 Altered Gene Expression of Matrix-Metalloproteinases 
and Tissue Inhibitors of Metalloproteinases in Patients 
Supported by Left Ventricular Assist Devices 
Peter Razeohi, Brian A. Bruckner, Larry O. Thompson, George P. Noon, Keith A. Youker, 
Heinrich Taegtmeyer, University of Texas Houston Medical School, Houston, Texas, 
Bay/or College of Medicine, Houston, Texas. 
Background: Left Ventricular Assist Device (LVAD) treatment improves cardiac function 
and decreases myocardial fibrosis and coltagen content. However, the underlying mech- 
anism is not understood. 
Hypothesis: Gone expression of key regulators of extra-cellular matrix degradation 
changes during LVAD support. 
Methods: Paired myocardial specimens (apex) from 7 patients with end-stage heart fail- 
ure (5 ischemic and 2 dilated cardiomyopathies) were obtained both at the time of 
implantation and explantation of a LVAD device. Using real-time quantitative RT-PCR, we 
measured transcript levels of the matrix-metalloproteinases 1 and 9 (MMP-1, MMP-9) 
and their specific inhibitors, the tissue inhibitor of metallopreteinases 1 and 4 (TIMP-1, 
TIMP-4). Data were normalized to the housekeeping gene beta-ectin. 
Results: There was no uniform response in transcripts investigated from patients sup- 
ported by LVADs. With mechanical unloading, MMP-1 transcript levels increased in 3, did 
not change in 2, and decreased in 2 patients. Gene expression of MMP-9 increased in 2, 
did not change in 1, and decreased in 4 patients, However, patients showing a decrease 
in MMP-9 transcript levels were on support for more than 3 weeks (mean: 9.8 ± 2.8 
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weeks), while those with unchanged or increased levels were between 1-3 weeks (mean: 
2.0 ± 0.6 weeks, p = 0.06) following LVAD treatment. TIMP-1 and TIMP-4 transcript lev- 
els increased in 4 and decreased in 3 patients. Changes in gene expression of those two 
transcripts correlated positively with each other during LVAD support (r2: 0.9, p < 0.001). 
There was no correlation between TIMP expression and time on support, and there was 
no reciprocal change in MMP expression. 
Conclusions: Myocardial gene expression of MMP-I., MMP-9, TIMP-1, and TIMP-4 do 
not change predictably during LVAD treatment, with the exception of MMP-9, which 
decreased after 3 weeks. These findings suggest a non-linear or biphasic response of 
MMP-9 expression with mechanical unloading. In addition, the positive correlation 
between changes in transcript levels of TIMP 1 and 4 suggest a common transcdptional 
mechanism. 
4:30 p.m. 
876-3 Expression Profiling of Genes in Eight Failing and 
Seven Nonfailing Human Hearts by Oligonucleotide 
Microarrays 
Fen-Lai Tan. Christine S. Moravec, Jianbo Li, Carolyn Apperson-Hansen, Patrick M. 
McCarthy, James B. Young, Meredith Bond, The Cleveland Clinic Foundation, Cleveland, 
Ohio. 
Background: Systematic expression profiling of genes at the global level in multiple 
human hearts in order to generate a complete complement of heart failure genes, has 
not been reported to date. 
Methods: Using oligonucleotide microarrays (Hu-6800, Affymetrix. Inc, CA), complemen- 
tary RNA isolated from left ventricular free wall of 7 non-failing (NF) and 8 failing human 
(FH) hearts (diagnosis: idiopathic dilated cardiomyopathy) was profiled for gene expres- 
sion. Using WUcoxon Rank-Sum test (P<0.05) and Student's T-test after log-transforma- 
tion (P<0.05), 1145 out of -7000 genes on the chip that are potentially differentially 
expressed between NF and FH hearts was generated. After elimination of genes with 
<1.5 fold change in expression level, 387 remained significant. To minimize the likelihood 
of false positives, a minimum mean average difference of 200 units was imposed. Of the 
387 genes, this additional cut-off point generated 115 genes with increased expression 
and 74 genes with decreased expression in the FH hearts. This comprehensive cut-off 
point is being confirmed by quantitative PCR. 
Results: 189 genes in 10 clusters were found differentially expressed between the NF 
and FH heads. As validation of this approach, changes in expression of a number of 
these genes are well documented, e.g. biomarkers for heart failure (ANF, BNP, troponin 
T1) were significantly increased, and several contractile proteins (e.g. a cardiac actin, 
myosin light chain) were significantly decreased. However, the majority of the genes 
have not previously been reported, e.g. up-regulated human brahma-related gene-1 
(BRG1, the ATPase subunit of SWI/SNF, involved in MyoD-mediated muscle differentia- 
tion) and thrombospondin-4 (an extracellullar Ca2+-binding adhesion protein, associated 
with increased dsk of early heart attack); down-regulated metallothionein (an inhibitor of 
the MAP kinase pathway, involved in resistance of Doxorubicin cardiotoxicity) and anti- 
chymotrypsin (a proteinase inhibitor, reported to attenuate myocardial ischemic injury). 
Conclusions: Novel findings include changes in expression of genes with a potential role 
in cardiac remodeling. 
4:45 p.m. 
876-4 Microarray Analysis of Changes in Gene Expression 
Following LVAD Support 
Nicholas R. DiPaola, Nicholas G. Smedira, Patrick M. McCarthy, James B. Young, 
Christine S. Moravec, Cleveland Clinic Foundation, Cleveland, Ohio. 
Data from our laboratory and others suggest that mechanically unloading the failing 
human head with a left ventricular assist device (LVAD) results in improved muscle func- 
tion and altered gene expression. Although provocative, such studies fail to address the 
interaction between genes or the possibility that groups of genes are coordinately regu- 
lated. We studied paired tissue samples from four patients before and after LVAD, using 
the Affymetdx Microarray system to simultaneously measure expression of 7000 genes. 
Patients were male, between 35 and 55 years of age, and had dilated cardiomyopathy. 
Duration of LVAD support was short (35 days) in two patients, and long (135 days) in two 
patients. Total RNA was prepared from tissue removed during LVAD implant and at trans- 
plant in all patients. RNA samples were reverse transcribed and in vitro translated into 
biotinylated cRNA, which was hybridized to Affymetdx human gene chip arrays. Analysis 
revealed the presence of 3476 genes, of which 196 were changed following LVAD sup- 
port in at least three of the patients (69 genes), or were differentially regulated by dura- 
tion of support (97 genes). Significant changes in gene expression in all four patients 
following mechanical unloading included a 4.5 fold decrease in atrial natriuratic factor 
and a 5.3 fold decrease in phosphotipase A2, as well as an 11.0 fold increase in in c-fos, 
a 4.3 fold increase in plasminogen activator inhibitor-t, a 3.4 fold increase in a zinc finger 
transcriptional repressor of TNF, and a 2.7 fold increase in protein tyrosine phosphatase. 
Genes which were differentially regulated based on duration included a 2.6 fold increase 
in GATA-4 in short duration patients, with no change following long duration support, as 
well as no change in protein phosphatase 2A during short term support, but a 2.0 fold 
increase following longer durations. Although much data remains to be analyzed, and the 
functional significance of these changes remains to be explored, the analysis of paired 
samples from LVAD-supported patients using Microarray techniques is a powerful 
approach for elucidating the coordinate changes in gene regulation following hemody- 
namic unloading of the failing human heart. 
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879 Cardiogenic Shock and Assist Devices 
Tuesday, March 19, 2002, 4:00 p.m.-5:00 p.m. 
Georgia World Congress Center, Room 367W 
4:00 p.m. 
879-1 Reverul of Cardiogenic Shock by Left Atrial-to-Femoral 
Arterial Bypass Assistance 
Holoer Thiele. Bemward Lauer, Enno Bouddot, Angela Genov, Rainer Hambrecht, 
Gerhard Schuler, University of Leipzig - Heart Center, Leipzig, Germany. 
Background: Mortality in cardiogenic shock following acute myocardial infarction remains 
at an unacceptable level despite interventional treatment of the underlying cause and 
use of intraaortic balloon counterpulsation. Frequently patients succumb to low cardiac 
output before the myocardium is able to recover from the ischemic event, A newly devel- 
oped left ventricular assist device (Tandem Heart pVAD, Cardiac Assist Technologies, 
Inc., Pittsburgh, Pennsylvania, USA) with active circulatory support might decrease mor- 
tality. 
Methods and results: Between 05/2000 and 0912001 in 19 consecutive patients with car- 
diogenic shook a percutaneous left atdat-to-femoral rterial bypass assist device was 
implanted. The device was connected to the patients' circulation by transseptal puncture 
of the left atdum; blood was returned to the lilac artery through an artedal cannula. In 13 
patients cardiogenic shook was caused by an acute myocardial infarction and in 6 by an 
infarct related ventricular septal defect. Mean duration of cardiac assist was 4±3 days. 
Mean flow of the device was 3.3±0.6 I/min. Before support cardiac index was 1.7±0.3 I/ 
min/qm and improved to 2,4±0.6 I/min/qm (p<0.001) with cardiac assist, Mean blood 
pressure increased from 64±8 mmHg to 80±9 mmHg (p<0,001). Pulmonary capillary 
wedge pressure, central venous pressure and mean pulmonary artery pressure were 
reduced from 20¢5, 12¢4 and 31±8 mmHg to 14±4, 9±3 and 23±6 mmHg (all p<0.01), 
respectively. Overall mortality was 42%. 
Conclusion: In patients with cardiogenic shock hemedynamic parameter can be substan- 
tially enhanced by use of a percutaneous left atdal-to-famoral arterial assist device, It 
provides up to 4.0 I/rain Of additional cardiac output, which is sufficient o revert cardio- 
genic shock in most patients. By diverting blood from the left atrium the left ventricular 
myocardium is unloaded, making recovery more likely following an ischemic event. The 
influence of this device on long-term prognosis warrants further investigations. 
4:15 p.m. 
879-2 The Paraaortic Counterpulsat ion Device Implanted on 
the Ascending Aorta Is Superior to an Equal Volume 
Intraaortic Bal loon Pump: Experimental Study 
John Terrevitis. Chdstos Charitos, Paraskevi Dolou, Argyrios Ntalianis, Stavros Drakos, 
Charalampos Pierakos, Kostas Chalkias, Panagiotis Papazoglou, John Nanas, 
Department of Clinical Therapeutics, University of Athens, Athens, Greece. 
Backround:We aimed to compare the hemodynamic effects of a 40ml total volume 
paraaodic counterpulsation device (PACD, stroke volume 30ml) to those of a 40ml 
intraaortic balloon pump (IABP), in an acute experimental porcine model of heart failure. 
Methods: In 6 pigs, weighting 53 to 64kgr, left ventdcular failure was induced with multi- 
ple ligations of small coronary arteries and propranolol and amiodarene infusion. The 
IABP was placed into the descending aorta and the PACD was implanted in the ascend- 
ing aorta via a 3cm vascular graft. Aortic pressures were recorded with and without 
mechanical assistance, provided by the IABP and the PACD, alternately. Cardiac output 
was monitored using a transit time ultrasound flowmetar placed on the pulmonary artery, 
Double Product (DP), Tension Time Index (l-rl), Diastolic Pressure Time Index (DPTI) 
and Endocardial Viability Ratio (EVR) were calculated. Both devices were driven by the 
Datascope 96 driving system. 
Results: The hemodynamic effectiveness of the devices was evaluated from their ability 
to reduce the aftedoed of the left ventricle and to provide diastolic aortic augmentation. 
Both significantly reduced the systolic aortic pressure (from 112 ± 18mmHg to 100 ± 17, 
p=0.000, and to 98 ± 23, p=0,000, using the IABP and the PACD, respectively) and the 
end diastolic aortic pressure, (from 82 ± 17mmHg to 74 ± 19, p=0.000 and to 50 ± 22, 
p=O.000, respectively). The PACD reduced the end diastolic aortic pressure more than 
the IABP (reduction of 42.6 ± 18.1% vs 11.0 ± 9.9%, p=0.000). The counterpulsation 
wave of the PACD was significantly greater than that of the IABP (augmentation of 44.8 ± 
22,2% vs 37.6 ± 15.6%, p=0.031). Both devices significantly lowered the end diastolic left 
ventricular pressure, DP and TTI and increased cardiac output, DPTI and EVR compara- 
bly, 
Conclusion: Both devices showed significant hemodynamic effects in left ventdcular 
function. Although the PACD was of a smaller stroke volume, it provided greater salutary 
hemodynamic effects. The simplicity of the implantation procedure of the PACD and the 
ability to be driven by the standard IABP driving system make it a promising device for 
wide use for mechanical assistance of the failing heart. 
